Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

27 Feb 2017

Abstract excerpt

Abstract Talazoparib inhibits PARP catalytic activity, trapping PARP1 on damaged DNA and causing cell death in BRCA1/2-mutated cells. We evaluated talazoparib therapy in this two-part, phase I, first-in-human trial. Antitumor activity, MTD, pharmacokinetics, and pharmacodynamics of once-daily talazoparib were determined in an open-label, multicenter, dose-escalation study (NCT01286987). The MTD was 1.0 mg/day,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28242752
DOI: 10.1158/2159-8290.cd-16-1250

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic CancersPMID 28242752Read ↗

Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancerSemantic proximity Read ↗

Talazoparib to treat BRCA-positive breast cancerSemantic proximity Read ↗

Evidence to date: talazoparib in the treatment of breast cancerSemantic proximity Read ↗

Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSemantic proximity Read ↗

Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program.Semantic proximity Read ↗

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis.Semantic proximity Read ↗

Safety, Pharmacokinetics, and Preliminary Efficacy of Talazoparib in Japanese Patients With Advanced Solid Tumors: Phase 1 StudySemantic proximity Read ↗

A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerSemantic proximity Read ↗

Advances in The Use of Parp Inhibitors For Brca1/2-Associated Breast Cancer: TalazoparibSemantic proximity Read ↗

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid TumorsSemantic proximity Read ↗

PARP inhibitors: a tsunami of indications in different malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.